Business / Finance

RSS

CVS Health signs definitive agreement to acquire Target's pharmacy and clinic businesses for $1.9 billion

CVS Health Corporation and Target Corporation announced today that they have entered into a definitive agreement for CVS Health to acquire Target's pharmacy and clinic businesses for approximately $1.9 billion. Through this agreement, CVS Health will acquire Target's more than 1,660 pharmacies across 47 states and operate them through a store-within-a-store format, branded as CVS/pharmacy.

15 Jun 2015

Genesis inks asset purchase agreement with Revera

Genesis HealthCare, one of the nation's largest providers of post-acute care, today announced that it has signed an asset purchase agreement with Revera Inc., a leading owner, operator and investor in the senior living sector, to acquire 24 of its skilled nursing facilities along with its contract rehabilitation business for $240 million.

15 Jun 2015

Taiho, Servier sign exclusive license agreement to develop and commercialize TAS-102 drug

Taiho Pharmaceutical Co., Ltd.(Japan) and Servier (France) announced on June 15 that they have entered into an exclusive license agreement on June 12, 2015 for the development and commercialization of TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride) in Europe and other countries.

15 Jun 2015

High throughput media preparation at the Institut Curie

The Institut Curie (Paris, France), a world leader in oncology research, has reported how it has standardised on using MEDIACLAVE media preparation and MEDIAJET automated petri dish filling systems from INTEGRA Biosciences to prepare its petri dishes.

From INTEGRA Biosciences 14 Jun 2015

Synthetic Genomics, Gen9 sign strategic licensing agreement for Febit intellectual property estate

Synthetic Genomics, Inc., a synthetic biology company advancing and innovating genomic science and technologies for transformative products and solutions, and Gen9 Inc., a pioneer in synthetic biology and leader in the development of scalable technologies for synthesizing and assembling DNA, today announced a strategic licensing agreement to leverage their respective strengths in synthetic biology technology development and commercialization.

11 Jun 2015

BRIM, Janssen announce strategic collaboration to develop effective treatment for dengue

BRIM Biotechnology, Inc., announced today that it has entered a Collaboration, Option and License Agreement with Janssen Pharmaceutica N.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

11 Jun 2015

Research progress with promising Alzheimer's drug Xanamem

Actinogen Limited (Actinogen Medical, ASX: ACW), an Australian biotechnology company focused on the development of novel treatments for Alzheimer’s disease and other major age-related neurodegenerative disorders, is pleased to announce that it has received ethics approval to initiate the third and final stage of the second Phase I trial of its lead Alzheimer’s drug candidate, Xanamem™.

11 Jun 2015

Elekta inks contract with Samsung Medical Center to provide the first Leksell Gamma Knife Icon to Asia

Elekta has signed a contract with one of Korea's most advanced hospitals, Samsung Medical Center in Seoul, to deliver the first Leksell Gamma Knife Icon to Asia.

From Elekta 10 Jun 2015

Physicians Endoscopy and Garden State Endoscopy Center finalize joint venture relationship

Physicians Endoscopy , and the physician partners of Garden State Endoscopy Center, are pleased to announce on May 6th, 2015, the two organizations finalized a joint venture relationship.

10 Jun 2015

Lynden International selects Cryoport as preferred cryogenic logistics provider

Cryoport, Inc., the leading provider of advanced cryogenic logistics solutions for the life sciences industry, serving markets including immunotherapies, stem cells, cell lines, clinical research organizations, vaccine manufacturers, animal health, and reproductive medicine, today announced that it has been selected by Lynden International as its preferred provider to support cold chain clinical trial logistics for underrepresented diseases in Africa.

10 Jun 2015

CTI BioPharma amends its existing loan agreement with Hercules Technology Growth Capital

CTI BioPharma Corp. today announced that it has amended its existing loan agreement with Hercules Technology Growth Capital, Inc. (Hercules). Pursuant to the amendment, Hercules agreed to provide term loans in an aggregate principal amount of up to $25.0 million under the facility, inclusive of amounts outstanding immediately prior to closing of the amendment.

10 Jun 2015

E-QURE inks distribution agreement with Rubifarm S.A.

E-QURE Corp. (OTCQB: EQUR), a Delaware Corporate engaged in the commercialization of its Bio-electrical Signal Therapy device ("BST Device"), a new and novel electrotherapy for the noninvasive treatment of hard to heal chronic wounds, today announced that the Company has signed its first distribution agreement with Rubifarm S.A., an Argentinian distributor specializing in medical devices, and. The agreement goes into effect immediately.

10 Jun 2015

Veeva, ZS Associates partner to speed up life sciences industry's move to customer-centric engagement

Veeva Systems and ZS Associates today announced a strategic partnership to accelerate the life sciences industry's move to more customer-centric engagement. The companies are joining forces to deliver innovation in customer data and data science for better marketing and sales effectiveness across all channels.

10 Jun 2015

Dr. Oz expands partnership with iHeartMedia

The Dr. Oz Show and iHeartMedia announced today they have expanded their partnership, increasing Dr. Oz's robust radio presence across iHeartMedia broadcast radio stations and on iHeartRadio, the all-in-one digital music and streaming radio service.

10 Jun 2015

PharmApprove, NDA Group partner to help life science companies navigate complex global environment

Two leading drug development and regulatory consultancies announced today that they have formed a new strategic alliance to help life science companies navigate an increasingly complex global environment.

10 Jun 2015

New marketplace lender for elective care treatments launched

PrimaHealth Credit, a new marketplace lender for elective healthcare treatments, launched today. The company is transforming how elective care providers and patients access healthcare financing by offering an easy-to-use mobile lending platform and patient friendly, non-punitive financing solutions. PrimaHealth Credit also announced the appointment of industry veteran Hugh Bleemer, the former President of ChaseHealthAdvance, as CEO.

9 Jun 2015

Lycera forms exclusive global collaboration with Celgene

Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, announced today the formation of an exclusive global collaboration with Celgene Corporation to take forward Lycera's proprietary pipeline for cancer and immune-mediated diseases.

9 Jun 2015

OncoSec Medical reports net loss of $14.7 million for FY 2015

OncoSec Medical Inc., a company developing DNA-based intratumoral cancer immunotherapies, today announced financial results for the nine months ended April 30, 2015.

9 Jun 2015

Clarus Ventures announces closure of Clarus Lifesciences III, L.P. and affiliated funds

Clarus Ventures, a leading life science investment firm, announced today the close of Clarus Lifesciences III, L.P. and affiliated funds, a $500 million fund, well above its initial $375 million target.

9 Jun 2015

Molecular Health, TestAnalytika sign distribution agreement for TreatmentMAP in Latin American region

Molecular Health signed an agreement with TestAnalytika to be its preferred distributor in the Latin American region at the 2015 ASCO Annual Meeting. TestAnalytika will begin to market and distribute Molecular Health's cancer treatment decision support product, TreatmentMAP, to patients, physicians, hospitals, laboratories, cancer centers and insurers in Latin America later this year.

8 Jun 2015

Business / Finance

CVS Health signs definitive agreement to acquire Target's pharmacy and clinic businesses for $1.9 billion

Genesis inks asset purchase agreement with Revera

Taiho, Servier sign exclusive license agreement to develop and commercialize TAS-102 drug

High throughput media preparation at the Institut Curie

Synthetic Genomics, Gen9 sign strategic licensing agreement for Febit intellectual property estate

BRIM, Janssen announce strategic collaboration to develop effective treatment for dengue

Research progress with promising Alzheimer's drug Xanamem

Elekta inks contract with Samsung Medical Center to provide the first Leksell Gamma Knife Icon to Asia

Physicians Endoscopy and Garden State Endoscopy Center finalize joint venture relationship

Lynden International selects Cryoport as preferred cryogenic logistics provider

CTI BioPharma amends its existing loan agreement with Hercules Technology Growth Capital

E-QURE inks distribution agreement with Rubifarm S.A.

Veeva, ZS Associates partner to speed up life sciences industry's move to customer-centric engagement

Dr. Oz expands partnership with iHeartMedia

PharmApprove, NDA Group partner to help life science companies navigate complex global environment

New marketplace lender for elective care treatments launched

Lycera forms exclusive global collaboration with Celgene

OncoSec Medical reports net loss of $14.7 million for FY 2015

Clarus Ventures announces closure of Clarus Lifesciences III, L.P. and affiliated funds

Molecular Health, TestAnalytika sign distribution agreement for TreatmentMAP in Latin American region

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Latest News